# Ideal Initial Bolus and Infusion Rate for Erector Spinae Plane Block Catheters

> **NCT03961048** · PHASE4 · WITHDRAWN · sponsor: **Virginia Commonwealth University**

## Conditions studied

- Pain, Postoperative
- Pain, Chest

## Interventions

- **DRUG:** Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution bilaterally
- **DRUG:** Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution unilaterally

## Key facts

- **NCT ID:** NCT03961048
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-07-23
- **Primary completion:** 2020-09
- **Final completion:** 2020-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Change in hospital protocol
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03961048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03961048, "Ideal Initial Bolus and Infusion Rate for Erector Spinae Plane Block Catheters". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03961048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*